Become an Associate PI


Become an Associate PI


The Associate Principal Investigator (PI) Scheme aims to develop junior doctors, nurses and allied health professionals to become the PIs of the future and provides formal recognition of a trainee’s engagement in NIHR Portfolio research studies through the conferment of Associate PI status endorsed by the NIHR and the Royal College of Surgeons of England.

The scheme is open to any doctor, nurse or allied health professional willing to make a significant contribution to the conduct and delivery of a study at a local level over a period of at least six months. On completion of the six month tenure, and the completion of the Associate PI Scheme learning course in NIHR Learn, applicants will receive a certificate confirming their Associate PI status, be acknowledged in the primary publication(s) generated from the study as well as gain the enhanced skills and understanding around the delivery of NIHR Portfolio research.

For further information see https://www.nihr.ac.uk/documents/associate-principal-investigator-pi-scheme/25040 , on which studies registered to this scheme are listed.

Please see the Urological studies below that are listed on the Associate PI scheme that you could get involved in.

PRIME (Prostate Imaging using MRI +/- contrast Enhancement (PRIME)) study
Sponsor: UCL, UK
Chief Investigator: Mr Veeru Kasivisvanathan
A study comparing bi-parametric MRI to multi-parametric MRI in the diagnosis of clinically significant prostate cancer (NCT04571840).
The standard way of diagnosing prostate cancer is to carry out a multiparametric MRI scan and targeted biopsy. This type of scan normally involves the insertion of a cannula in one of your veins, through which contrast is given.
Another type of MRI scan (biparametric) can be performed that does not require contrast, and therefore does not require the insertion of a cannula. We currently do not know for certain whether using this type of MRI will allow us to detect the same, more or less prostate cancer than if we use the standard (multiparametric) type of MRI. Current evidence supports the idea that using biparametric MRI may detect a similar amount of cancer to when it is not used but one advantage is it may allow a man to have a scan without contrast. Because the use of contrast comes with a risk of allergy and potential side effects, this would be an improvement over the standard (multiparametric) MRI if the scan was just as good in identifying suspicious parts of the prostate.
Click here for further information and current trial status: https://www.ucl.ac.uk/surgery/research/department-targeted-intervention/urology/prime-trial-information

Copyright British Urology Researchers in Surgical Training (BURST) Research Collaborative @ 2021. Join Us as a Sponsor